Opinion/decision on a Paediatric investigation plan (PIP): Ezeprogind, decision type: , therapeutic area: , PIP number: P/0538/2022

Opinion/decision on a Paediatric investigation plan (PIP): Messenger RNA encoding Cas9 and single guide RNA targeting the human TTR gene, decision type: , therapeutic area: , PIP number: P/0532/2022

Veterinary medicines European public assessment report (EPAR): CaniLeish, Leishmania infantum excreted secreted proteins, Date of authorisation: 14/03/2011, Revision: 2, Status: Withdrawn

Opinion/decision on a Paediatric investigation plan (PIP): Eplontersen, decision type: , therapeutic area: , PIP number: P/0534/2022

Opinion/decision on a Paediatric investigation plan (PIP): cyanocobalamin,Diclofenac (potassium),pyridoxine (hydrochloride),Thiamine (hydrochloride), decision type: , therapeutic area: , PIP number: P/0499/2022

Opinion/decision on a Paediatric investigation plan (PIP): Acetylsalicylic acid,rivaroxaban, decision type: , therapeutic area: , PIP number: P/0516/2022

Opinion/decision on a Paediatric investigation plan (PIP): eplerenone,Torasemide, decision type: , therapeutic area: , PIP number: P/0530/2022

Opinion/decision on a Paediatric investigation plan (PIP): Indapamide,valsartan, decision type: , therapeutic area: , PIP number: P/0547/2022

Opinion/decision on a Paediatric investigation plan (PIP): 2-[4-Methoxy-3-(2-m-tolyl-ethoxy)-benzoylamino]-indan-2-carboxylic acid, decision type: , therapeutic area: , PIP number: P/0482/2022

Human medicines European public assessment report (EPAR): Prolia, denosumab, Bone Resorption;Osteoporosis, Postmenopausal, Date of authorisation: 26/05/2010, Revision: 27, Status: Authorised